2025-03-17 カロリンスカ研究所(KI)
©m-sato@tii
<関連情報>
- https://news.ki.se/continued-medication-important-for-heart-failure-patients
- https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.072855
心不全患者におけるガイドライン指示の内科的治療の中止と駆出率の改善 Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction
Christian Basile, MD, Felix Lindberg, MD, PhD, Lina Benson, MSc, Federica Guidetti, MD, Ulf Dahlström, MD, PhD, Massimo Francesco Piepoli, MD, PhD, Peter Mol, PharmD, PhD, Raffaele Scorza, MD, PhD, Aldo Pietro Maggioni, MD, Lars H. Lund, MD, PhD, and Gianluigi Savarese, MD, PhD
Circulation Published: 17 March 2025
DOI:https://doi.org/10.1161/CIRCULATIONAHA.124.072855
Abstract
BACKGROUND:
Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study assessed rates of, patient profiles, and associations with morbidity/mortality of renin-angiotensin inhibitors (RASi), angiotensin receptor–neprilysin inhibitors (ARNi), beta-blockers (BBL), and mineralocorticoid receptor antagonists (MRA) withdrawal in patients with HF with improved EF.
METHODS:
Patients with a first recorded EF <40% and a later EF ≥40% from the Swedish HF registry between June 11, 2000, and December 31, 2023, were included in this retrospective observational study. Withdrawal was defined as a patient on treatment at the first (reduced) but not at the second (improved) registration. The association between withdrawal and time to first cardiovascular mortality/hospitalization for HF with censoring at 1 year was assessed by Cox regression model using overlap weighting.
RESULTS:
Of 8728 patients with HF with improved EF (median age, 70 years [25th to 75th percentile, 61–78], 2611 [29.9%] women), 96%, 94%, and 46% received RASi/ARNi, BBL, and MRA, respectively, when EF was <40%. The withdrawal rates at the time of the improved EF registration were 4.4% for RASi/ARNi, 3.3% for BBL, and 17.2% for MRA. Predictors of withdrawal included lower use of other HF medications, higher EF at the later EF registration, and a longer time between the 2 EF assessments. After weighting, withdrawal was independently associated with a higher risk of cardiovascular mortality/hospitalization for HF by 38% for RASi/ARNi and 36% for MRA, but not for BBL. Withdrawal of BBL was associated with a higher risk of the primary outcome in the subgroup of patients with an improved EF of 40% to 49% versus ≥50% (P-interaction 0.03).
CONCLUSIONS:
In patients with HF with improved EF, HF therapy withdrawal was rare. Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year. No association was found for BBL withdrawal, albeit with a significant heterogeneity for EF at improvement, suggesting better outcomes with continuing BBL only until EF improves up to 50%. These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with HF with improved EF.
